Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Hybridon licenses VEGF rights to Alnylam for ocular indications

Aug. 10, 2004

Ista submits sNDA for Vitrase as spreading agent

Aug. 10, 2004

Approvable letter for Lumigan-timolol combination

Aug. 5, 2004

Alcon patent covers new 5-HT2 agonists for glaucoma therapy

Aug. 5, 2004

ISTA launches Istalol for glaucoma

Aug. 2, 2004

FDA accepts for review Xibrom NDA

July 28, 2004

AzaSite enters two phase III studies for acute bacterial conjunctivitis

July 26, 2004

Completion of financing round at Acuity

July 21, 2004

Merck & Co. and Alnylam collaborate on RNAi therapeutics for ocular diseases

July 6, 2004

Alcon files second portion of Retaane rolling NDA

July 6, 2004

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...